AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 272: E422-E428, 1997;
0193-1849/97 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sips, A. J.
Right arrow Articles by van der Vijgh, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sips, A. J.
Right arrow Articles by van der Vijgh, W. J.

AJP - Endocrinology and Metabolism, Vol 272, Issue 3 E422-E428, Copyright © 1997 by American Physiological Society

ARTICLES

Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption

A. J. Sips, R. Barto, J. C. Netelenbos and W. J. van der Vijgh
Department of Endocrinology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.

The applicability of stable strontium as a marker for measuring intestinal calcium absorption is mainly dependent on the validity of the assumption that calcium and strontium are absorbed with a constant ratio. Up to now, it is not clear whether this ratio is affected by intervention therapy. Therefore, preclinical screening of this ratio before and after treatment is indispensable for a clinical calcium absorption test based on the use of stable strontium as a marker. We studied the effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D(3)], a potent enhancer of active intestinal calcium absorption, on the pharmacokinetics of both calcium-45 and strontium in adult male rats, in a short-term dose-finding study [0-50 ng 1,25(OH)2D(3)/100 g body weight] and also in a placebo-controlled study in which 12.5 ng 1,25(OH)2D(3)/100 g body weight were applied to assess the long-term pharmacokinetics. The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively. These findings demonstrate that intestinal strontium absorption has, like intestinal calcium absorption, an active component. Moreover, they underscore the applicability of stable strontium as a tool for investigating calcium absorption under various conditions.


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
A. Zittermann, P. Bock, C. Drummer, K. Scheld, M. Heer, and P. Stehle
Lactose does not enhance calcium bioavailability in lactose-tolerant, healthy adults
Am. J. Clinical Nutrition, April 1, 2000; 71(4): 931 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Dijkgraaf-ten Bolscher, J. C. Netelenbos, R. Barto, and W. J.F. van der Vijgh
Strontium as a Marker for Intestinal Calcium Absorption: The Stimulatory Effect of Calcitriol
Clin. Chem., February 1, 2000; 46(2): 248 - 251.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Vezzoli, A. Caumo, I. Baragetti, S. Zerbi, P. Bellinzoni, A. Centemero, A. Rubinacci, G. Moro, D. Adamo, G. Bianchi, et al.
Study of Calcium Metabolism in Idiopathic Hypercalciuria by Strontium Oral Load Test
Clin. Chem., February 1, 1999; 45(2): 257 - 261.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online